Verified Nov 2026
Other
·

Boulogne-Billancourt, Ile-de-France
·
Since 1929
Ipsen is a biopharmaceutical company headquartered in Boulogne-Billancourt, France, founded in 1929. It employs 5,000–10,000 people and generates estimated revenue of $1–5 billion annually. The company develops and commercializes medicines in oncology, rare diseases, and neuroscience, serving medical and industrial sectors across 88 countries. It expanded its early development pipeline through an antibody drug conjugate partnership in late 2025.
Epizyme at a glance
Revenue
$1-5B
Est. band
Employees
5,000-10,000
Founded
1929
Headquarters
Boulogne-Billancourt, Ile-de-France
Industries
Automotive
Electric Vehicles
Medical
Renewable Energy
Industrial Equipment
Overview
Ipsen is a biopharmaceutical company headquartered in Boulogne-Billancourt, France, founded in 1929. It employs 5,000–10,000 people and generates estimated revenue of $1–5 billion annually. The company develops and commercializes medicines in oncology, rare diseases, and neuroscience, serving medical and industrial sectors across 88 countries. It expanded its early development pipeline through an antibody drug conjugate partnership in late 2025.
At a glance
Attribute | Detail |
|---|---|
Founded | 1929 |
Headquarters | Boulogne-Billancourt, Ile-de-France |
Employees | 5,000-10,000 |
Revenue | $1-5B (estimated) |
What Epizyme makes
The company operates four global research and development hubs and three pharmaceutical development centers, focusing on oncology treatments such as Cabometyx and Onivyde, rare disease therapies including Bylvay, and neuroscience medicines.
Latest developments
2026-03-09 — Ipsen Announcement (ipsen.com)
2026-01-30 — Ipsen expands pre-clinical pipeline in rare neurodegenerative diseases - Global (ipsen.com)
2025-12-22 — Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate (ipsen.com)
2025-10-22 — Ipsen to acquire ImCheck Therapeutics, expanding its leadership in oncology, strengthening its pipeline (ipsen.com)
Company details
Ipsen ranks among the top 15 biopharmaceutical companies in oncology sales globally and prioritizes external innovation partnerships to strengthen its specialty care pipeline. Epizyme was founded in 1929, has an estimated 5,000-10,000 employees, and is headquartered in Boulogne-Billancourt, Ile-de-France.
Frequently asked questions
What does Epizyme do?
Ipsen is a biopharmaceutical company headquartered in Boulogne-Billancourt, France, founded in 1929. It employs 5,000–10,000 people and generates estimated revenue of $1–5 billion annually. The company develops and commercializes medicines in oncology, rare diseases, and neuroscience, serving medical and industrial sectors across 88 countries. It expanded its early development pipeline through an antibody drug conjugate partnership in late 2025.
Where is Epizyme headquartered?
Epizyme is headquartered in Boulogne-Billancourt, Ile-de-France (65 Quai Georges Gorse, Boulogne-Billancourt, Ile-de-France, 92100).
When was Epizyme founded?
Epizyme was founded in 1929.
How big is Epizyme?
Epizyme has an estimated 5,000-10,000 employees, with revenue in the $1-5B range (estimated).
Related suppliers
Explore other suppliers in the LightSource directory:
Last verified Nov 2026. Is this your company? Request a correction.
Location & contact
Evaluating suppliers like these?
This profile is part of a public-data sample of the full LightSource directory. Book a demo to see the full LightSource marketplace and supplier discovery platform — 1M+ credible suppliers, with AI-run sourcing events.
